Tuberculosis and Respiratory Diseases

  • 제60권5호
  • /
  • Pages.497-509
  • /
  • 2006
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지

체외 Interferon-gamma 검사를 이용한 결핵감염의 진단

Diagnosis of Mycobacterium tuberculosis Infection using Ex-vivo interferon-gamma Assay

  • 이정연 (건국대학교 의료원 충주병원 호흡기내과) ;
  • 심태선 (울산대학교 의과대학 서울아산병원 호흡기내과)
  • Lee, Jung Yeon (Division of Pulmonary Medicine, Department of Internal Medicine, Konkuk University Medical Center) ;
  • Shim, Tae Sun (Division of Pulmonary & Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center)
  • 발행 : 2006.05.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Until recently, the tuberculin skin test (TST) has been the only tool available for diagnosing a latent TB infection. However, the development of new diagnostic tools, using the Mycobacterium tuberculosis (MTB)-specific early secreted antigenic target 6 (ESAT-6) and culture filtrate protein 10 (CFP-10) antigens, should improve the control of tuberculosis (TB) by allowing a more accurate identification of a latent TB infection (LTBI). Antigen-specific interferon-gamma ($IFN-{\gamma}$) assays have greater specificity in BCG-vaccinated individuals, and as less biased by nontuberculous mycobacterial infections. Many comparative studies have suggested that those assays have a higher specificity than the TST, and the sensitivity of these assays are expected to remarkably improved if more MTB-specific antigens can become available. Nevertheless, the major obstacle to the widespread use of these tests is the limited financial resources. Similar to other diagnostic tests, the predictive value of $IFN-{\gamma}$ assays depends on the prevalence of a MTB infection in the population being tested. Therefore, prospective studies will be meeded to establish the applicability of these new assays at multiple geographic locations among patients of different ethnicities, and to determine if the $IFN-{\gamma}$ responses can indicate those with a high risk of progressing to active TB.

키워드

참고문헌

  1. Cooper AM, Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993;178:2243-7 https://doi.org/10.1084/jem.178.6.2243
  2. Newport MJ, Huxley CM, Huston S, Hawrylowicz CM, Oostra BA, Williamson R, et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996;335:1941-9 https://doi.org/10.1056/NEJM199612263352602
  3. Wongtim S, Silachamroon U, Ruxrungtham K, Udompanich V, Limthongkul S, Charoenlap P, et al. Interferon gamma for diagnosing tuberculous pleural effusions. Thorax 1999;54:921-4 https://doi.org/10.1136/thx.54.10.921
  4. Ogawa K, Koga H, Yang B, Fukuda M, Ohno H, Yamamoto Y, et al. Differential diagnosis of tuberculous pleurisy by the measurement of cytokine concentration in pleural effusion. Kekkaku 1996;71:663-9
  5. Barnes PF, Fong SJ, Brennan PJ, Twomey PE, Mazumder A, Modlin RL. Local production of tumor necrosis factor and IFN-gamma in tuberculous pleuritis. J Immunol 1990;145:149-54
  6. Ribera E, Martinez Vasquez JM, Ocana I, Ruiz I, Jiminez JG, Encabo G, et al. Diagnostic value of ascites gamma interferon levels in tuberculous peritonitis: comparison with adenosine deaminase activity. Tubercle 1991;72:193-7 https://doi.org/10.1016/0041-3879(91)90007-F
  7. Burgess LJ, Reuter H, Carstens ME, Taljaard JJ, Doubell AF. The use of adenosine deaminase and interferon-gamma as diagnostic tools for tuberculous pericarditis. Chest 2002;122:900-5 https://doi.org/10.1378/chest.122.3.900
  8. Ribeiro-Rodrigues R, Resende Co T, Johnson JL, Ribeiro F, Palaci M, Sa RT, et al. Sputum cytokine levels in patients with pulmonary tuberculosis as early markers of mycobacterial clearance. Clin Diagn Lab Immunol 2002;9:818-23
  9. Tsao TC, Huang CC, Chiou WK, Yang PY, Hsieh MJ, Tsao KC. Levels of interferon-gamma and interleukin-2 receptor-alpha for bronchoalveolar lavage fluid and serum were correlated with clinical grade and treatment of pulmonary tuberculosis. Int J Tuberc Lung Dis 2002;6:720-7
  10. Koh WJ, Kwon OJ, Suh GY, Chung MP, Kim H, Lee NY, et al. Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis. J Korean Med Sci 2004;19:167-71 https://doi.org/10.3346/jkms.2004.19.2.167
  11. Suarez-Mendez R, Garcia-Garcia I, Fernandez-Olivera N, Valdes-Quintana M, Milanes-Virelles MT, Carbonell D, et al. Adjuvant interferon gamma in patients with drug-resistant pulmonary tuberculosis: a pilot study. BMC Infect Dis 2004;4:44 https://doi.org/10.1186/1471-2334-4-44
  12. Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 1997;349:1513-5 https://doi.org/10.1016/S0140-6736(96)12273-X
  13. Kim EK, Shim TS, Lee JY, Oh YM, Lim CM, Lee SD, et al. The adjuvant effect of subcutaneous interferon-gamma in the treatment of refractory multidrug-resistant pulmonary tuberculosis. Tuberc Respir Dis 2004;57:226-33 https://doi.org/10.4046/trd.2004.57.3.226
  14. Mazurek GH, LoBue PA, Daley CL, Bernardo J, Lardizabal AA, Bishai WR, et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 2001;286:1740-7 https://doi.org/10.1001/jama.286.14.1740
  15. Huebner RE, Schein MF, Bass JB Jr. The tuberculin skin test. Clin Infect Dis 1993;17:968-75 https://doi.org/10.1093/clinids/17.6.968
  16. Jasmer RM, Nahid P, Hopewell PC. Clinical practice: latent tuberculosis infection. N Engl J Med 2002;347:1860-6 https://doi.org/10.1056/NEJMcp021045
  17. Mori T, Sakatani M, Yamagishi F, Takashima T, Kawabe Y, Nagao K, et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004;170:59-64 https://doi.org/10.1164/rccm.200402-179OC
  18. Brock I, Weldingh K, Lillebaek T, Follmann F, Andersen P. Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. Am J Respir Crit Care Med 2004;170:65-9 https://doi.org/10.1164/rccm.200402-232OC
  19. Mazurek GH, Jereb J, LoBue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005;54:49-55
  20. Cellestis Ltd. QuantiFERON-TB Gold (In-Tube Method) package insert. Cat. no. 0599 0201. Victoria, Australia 2004
  21. Chapman AL, Munkanta M, Wilkinson KA, Pathan AA, Ewer K, Ayles H, et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 2002;16:2285-93 https://doi.org/10.1097/00002030-200211220-00008
  22. Hill PC, Brookes RH, Fox A, Fielding K, Jeffries DJ, Jackson-Sillah D, et al. Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis ofMycobacterium tuberculosis infection against a gradient of exposure in the Gambia. Clin Infect Dis 2004;38:966-73 https://doi.org/10.1086/382362
  23. Arend SM, Engelhard AC, Groot G, de Boer K, Andersen P, Ottenhoff TH, et al. Tuberculin skin testing compared with T-cell responses to Mycobacterium tuberculosis-specific and nonspecific antigens for detection of latent infection in persons with recent tuberculosis contact. Clin Diagn Lab Immunol 2001;8:1089-96
  24. Lein AD, von Reyn CF, Ravn P, Horsburgh CR Jr, Alexander LN, Andersen P. Cellular immune responses to ESAT-6 discriminate between patients with pulmonary disease due toMycobacterium avium complex and those with pulmonary disease due to Mycobacterium tuberculosis. Clin Diagn Lab Immunol 1999;6:606-9
  25. Wood PR, Corner LA, Plackett P. Development of a simple, rapid in vitro cellular assay for bovine tuberculosis based on the production of gamma interferon. Res Vet Sci 1990;49:46-9
  26. Desem N, Jones SL. Development of a human gamma interferon enzyme immunoassay and comparison with tuberculin skin testing for detection of Mycobacterium tuberculosis infection. Clin Diagn Lab Immunol 1998;5:531-6
  27. Mazurek GH, Villarino ME. Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. MMWR Recomm Rep 2003;52:15-8
  28. Fietta A, Meloni F, Cascina A, Morosini M, Marena C, Troupioti P, et al. Comparison of a whole-blood interferon-gamma assay and tuberculin skin testing in patients with active tuberculosis and individuals at high or low risk of Mycobacterium tuberculosis infection. Am J Infect Control 2003;31:347-53 https://doi.org/10.1016/S0196-6553(02)48240-5
  29. Johnson PD, Stuart RL, Grayson ML, Olden D, Clancy A, Ravn P, et al. Tuberculin-purified protein derivative-, MPT-64-, and ESAT-6-stimulated gamma interferon responses in medical students before and after Mycobacterium bovis BCG vaccination and in patients with tuberculosis. Clin Diagn Lab Immunol 1999;6:934-7
  30. Lalvani A, Nagvenkar P, Udwadia Z, Pathan AA, Wilkinson KA, Shastri JS, et al. Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latentMycobacterium tuberculosisinfection in healthy urban Indians. J Infect Dis 2001;183:469-77 https://doi.org/10.1086/318081
  31. Kang YA, Lee HW, Yoon HI, Cho B, Han SK, Shim YS, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. JAMA 2005;293:2756-61 https://doi.org/10.1001/jama.293.22.2756
  32. Ferrara G, Losi M, Meacci M, Meccugni B, Piro R, Roversi P, et al. Routine hospital use of a commercial whole blood interferon-gamma assay for tuberculosis infection. Am J Respir Crit Care Med 2005;172:631-5 https://doi.org/10.1164/rccm.200502-196OC
  33. Brock I, Ruhwald M, Lundgren B, Westh H, Mathiesen LR, Ravn P. Latent tuberculosis in HIV positive, diagnosed by the M. Tuberculosis specific interferon gamma test. Respir Res 2006;7:56 https://doi.org/10.1186/1465-9921-7-56
  34. Mahomed H, Hughes EJ, Hawkridge T, Minnies D, Simon E, Little F, et al. Comparison of mantoux skin test with three generations of a whole blood FNgamma assay for tuberculosis infection. Int J Tuberc Lung Dis 2006;10:310-6
  35. Lalvani A, Pathan AA, McShane H, Wilkinson RJ, Latif M, Conlon CP, et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med 2001;163:824-8 https://doi.org/10.1164/ajrccm.163.4.2009100
  36. Pathan AA, Wilkinson KA, Klenerman P, McShane H, Davidson RN, Pasvol G, et al. Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 2001;167:5217-25 https://doi.org/10.4049/jimmunol.167.9.5217
  37. Lalvani A, Brookes R, Wilkinson RJ, Malin AS, Pathan AA, Andersen P, et al. Human cytolytic and interferon gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 1998;95:270-5 https://doi.org/10.1073/pnas.95.1.270
  38. Pathan AA, Wilkinson KA, Wilkinson RJ, Latif M, McShane H, Pasvol G, et al. High frequencies of circulating IFN-gamma-secreting CD8 cytotoxic T cells specific for a novel MHC class I-restrictedMycobacterium tuberculosis epitope in M. tuberculosis-infected subjects without disease. Eur J Immunol 2000;30:2713-21 https://doi.org/10.1002/1521-4141(200009)30:9<2713::AID-IMMU2713>3.0.CO;2-4
  39. Lalvani A, Pathan AA, Durkan H, Wilkinson KA, Whelan A, Deeks JJ, et al. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 2001;357:2017-21 https://doi.org/10.1016/S0140-6736(00)05115-1
  40. Ewer K, Deeks J, Alvarez L, Bryant G, Waller S, Andersen P, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 2003;361:1168-73 https://doi.org/10.1016/S0140-6736(03)12950-9
  41. Shams H, Weis SE, Klucar P, Lalvani A, Moonan PK, Pogoda JM, et al. Enzyme-linked immunospot and tuberculin skin testing to detect latent tuberculosis infection. Am J Respir Crit Care Med 2005;172:1161-8 https://doi.org/10.1164/rccm.200505-748OC
  42. Richeldi L, Ewer K, Losi M, Bergamini BM, Roversi P, Deeks J, et al. T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure. Am J Respir Crit Care Med 2004;170:288-95 https://doi.org/10.1164/rccm.200403-307OC
  43. American Thoracic Society/Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221-47 https://doi.org/10.1164/ajrccm.161.supplement_3.ats600
  44. Piana F, Codecasa LR, Besozzi G, Migliori GB, Cirillo DM. Use of commercial interferon-gamma assays in immunocompromised patients for tuberculosis diagnosis. Am J Respir Crit Care Med 2006;173:130 https://doi.org/10.1164/ajrccm.173.1.130
  45. Piana F, Codecasa LR, Cavallerio P, Ferrarese M, Migliori GB, Barbarano L, et al. Use of a T-cell based test for detection of TB infection among immunocompromised patients. Eur Respir J 2006. (In press)
  46. Scholvinck E, Wilkinson KA, Whelan AO, Martineau AR, Levin M, Wilkinson RJ. Gamma interferon-based immunodiagnosis of tuberculosis: comparison between whole-blood and enzyme-linked immunospot methods. J Clin Microbiol 2004;42:829-31 https://doi.org/10.1128/JCM.42.2.829-831.2004
  47. Goletti D, Vincenti D, Carrara S, Butera O, Bizzoni F, Bernardini G, et al. Selected RD1 peptides for active tuberculosis diagnosis: comparison of a gamma interferon whole-blood enzyme-linked immunosorbent assay and an enzyme-linked immunospot assay. Clin Diagn Lab Immunol 2005;12:1311-6
  48. Lee JY, Choi HJ, Park IN, Hong SB, Oh YM, Lim CM, et al. Comparison of two commercial interferon gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006. (In press)
  49. Ferrara G, Losi M, D'Amico R, Roversi P, Piro R, Meacci M, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006;367:1328-34 https://doi.org/10.1016/S0140-6736(06)68579-6
  50. Stuart RL, Olden D, Johnson PD, Forbes A, Bradley PM, Rothel JS, et al. Effect of anti-tuberculosis treatment on the tuberculin interferon-gamma response in tuberculin skin test (TST) positive health care workers and patients with tuberculosis. Int J Tuberc Lung Dis 2000;4:555-61
  51. Carrara S, Vincenti D, Petrosillo N, Amicosante M, Girardi E, Goletti D. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis 2004;38:754-6 https://doi.org/10.1086/381754
  52. Markova R, Drenska R, Terzieva V, Todorova Y, Dimitrov V, Nikolova M. The application of the T spot-TB assay in Bulgarian patients with tuberculosis infection. Probl Infect Parasit Dis 2005;33:10-11
  53. Aiken AM, Hill PC, Fox A, McAdam KP, Jackson-Sillah DJ, Lugos MD, et al. Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases. BMC Infect Dis 2006;6:66 https://doi.org/10.1186/1471-2334-6-66
  54. Kim YS, Cho SA, Park MS, Chung JH, Hwang SY, Kim SK, et al. Change of Interferon gamma production in patients with active tuberculosis after treatment. Am J Respir Crit Care Med 2004:A376
  55. Zinkernagel RM, Bachmann MF, Kundig TM, Oehen S, Pirchet H, Hengartner H. On immunological memory. Annu Rev Immunol 1996;14:333-67 https://doi.org/10.1146/annurev.immunol.14.1.333
  56. Hengel RL, Allende MC, Dewar RL, Metcalf JA, Mican JM, Lane HC. Increasing CD4+ T cells specific for tuberculosis correlate with improved clinical immunity after highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2002;18:969-75 https://doi.org/10.1089/088922202760265632
  57. Wu-Hsieh BA, Chen CK, Chang JH, Lai SY, Wu CH, Cheng WC, et al. Long-lived immune response to early secretory antigenic target 6 in individuals who had recovered from tuberculosis. Clin Infect Dis 2001;33:1336-40 https://doi.org/10.1086/323044
  58. Hill PC, Fox A, Jeffries DJ, Jackson-Sillah D, Lugos MD, Owiafe PK, et al. Quantitative T cell assay reflects infectious load ofMycobacterium tuberculosis in an endemic case contact model. Clin Infect Dis 2005;40:273-8 https://doi.org/10.1086/427030
  59. Godkin AJ, Thomas HC, Openshaw PJ. Evolution of epitope-specific memory CD4(+) T cells after clearance of hepatitis C virus. J Immunol 2002;169:2210-4 https://doi.org/10.4049/jimmunol.169.4.2210
  60. Sousa AO, Wargnier A, Poinsignon Y, Simonney N, Gerber F, Lavergne F, et al. Kinetics of circulating antibodies, immune complex and specific antibodysecreting cells in tuberculosis patients during 6 months of antimicrobial therapy. Tuber Lung Dis 2000;80:27-33 https://doi.org/10.1054/tuld.1999.0230
  61. Park IN. Evaluation of the response to antituberculous treatment using ex-vivo interferon- gamma assay. Tuberc Respir Dis 2005;59:55
  62. Liebeschuetz S, Bamber S, Ewer K, Deeks J, Pathan AA, Lalvani A. Diagnosisof tuberculosis in South African children with a T-cell-based assay: a prospective cohort study. Lancet 2004;364:2196-203 https://doi.org/10.1016/S0140-6736(04)17592-2
  63. Ravn P, Munk ME, Andersen AB, Lundgren B, Lundgren JD, Nielsen LN, et al. Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. Clin Diagn Lab Immunol 2005;12:491-6
  64. Vordermeier HM, Whelan A, Cockle PJ, Farrant L, Palmer N, Hewinson RG. Use of synthetic peptides derived from the antigens ESAT-6 and CFP-10 for differential diagnosis of bovine tuberculosis in cattle. Clin Diagn Lab Immunol 2001;8:571-8
  65. Liu XQ, Dosanjh D, Varia H, Ewer K, Cockle P, Pasvol G, et al. Evaluation of T-cell responses to novel RD1- and RD2-encoded Mycobacterium tuberculosis gene products for specific detection of human tuberculosis infection. Infect Immun 2004;72:2574-81 https://doi.org/10.1128/IAI.72.5.2574-2581.2004
  66. Brock I, Weldingh K, Leyten EM, Arend SM, Ravn P, Andersen P. Specific T-cell epitopes for immunoassay-based diagnosis ofMycobacterium tuberculosis infection. J Clin Microbiol 2004;42:2379-87 https://doi.org/10.1128/JCM.42.6.2379-2387.2004
  67. Wrighton-Smith P, Zellweger JP. Direct costs of three models for the screening of latent tuberculosis infection. Eur Respir J 2006. (In press)
  68. Doherty TM, Demissie A, Olobo J, Wolday D, Britton S, Eguale T, et al. Immune responses to theMycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol 2002;40:704-6 https://doi.org/10.1128/JCM.40.2.704-706.2002